文献速递运动医学关节外科

同种异体富血小板血浆与皮质类固醇注射治疗肩袖疾病:一项随机对照试验

Allogeneic Platelet-Rich Plasma Versus Corticosteroid Injection for the Treatment of Rotator Cuff Disease: A Randomized Controlled Trial.
PubMed 文献 · J Bone Joint Surg Am · 2020-01-01

这项评估者盲法随机对照试验纳入60例临床和结构确诊的肩袖疾病患者,比较超声引导下肩峰下注射4 mL同种异体纯富血小板血浆(PRP)与4 mL混合液(1 mL 40 mg/mL曲安奈德加3 mL 2%利多卡因)的安全性和疗效。两组均无治疗相关不良事件,1个月时Constant评分无显著差异;6个月时PRP组DASH评分、整体功能和外旋显著优于皮质类固醇组,其余临床结局无显著差异。PRP组疼痛、肌力和功能评分缓慢稳步改善至6个月,而皮质类固醇组起效快但未进一步改善。

要点

  • 同种异体纯PRP肩峰下注射治疗肩袖疾病未发生治疗相关不良事件。
  • 1个月时PRP组与皮质类固醇组Constant评分无显著差异。
  • 6个月时PRP组DASH评分、整体功能和外旋显著优于皮质类固醇组。

核心结论

  • 同种异体PRP注射治疗肩袖疾病是安全的,但在6个月内的疼痛缓解和功能改善方面并不确定优于皮质类固醇注射。
  • 6个月时PRP组DASH评分、整体功能和外旋显著优于类固醇组。
  • 总体而言,PRP在6个月内缓慢但稳步地减轻疼痛并改善肩部功能,而皮质类固醇未出现这种持续改善。

研究设计与样本

  • 两组平行、评估者盲法随机对照试验,共纳入60例临床和结构确诊的肩袖疾病患者。
  • 患者随机接受超声引导下肩峰下注射4 mL同种异体纯PRP或4 mL混合液(1 mL 40 mg/mL曲安奈德加3 mL 2%利多卡因)。
  • 主要结局为安全性和1个月时Constant评分,次要结局包括疼痛、活动度、肌力、功能评分及整体满意度和功能。
  • 证据等级为治疗性I级。

主要发现

  • 无治疗相关不良事件。
  • 1个月时PRP组与皮质类固醇组Constant评分无显著差异。
  • 6个月时PRP组DASH评分、整体功能和外旋显著优于皮质类固醇组,其他临床结局无显著差异。
  • PRP组所有疼痛测量、冈上肌和冈下肌肌力及5项功能评分在注射后缓慢稳步改善,6个月时较注射前显著改善;皮质类固醇组起效迅速但未进一步改善。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of platelet-rich plasma (PRP) for the treatment of rotator cuff disease is still controversial. The purpose of the present study was to investigate the safety and efficacy of a fully characterized allogeneic pure PRP injection into the subacromial space of patients with rotator cuff disease in comparison with corticosteroid injection. METHODS: A 2-group, parallel, assessor-blinded, randomized controlled trial was conducted. A total of 60 patients with clinically and structurally diagnosed rotator cuff disease were randomly assigned to receive a subacromial injection of either 4 mL of allogeneic pure PRP or a 4-mL mixture of 1 mL of 40-mg/mL triamcinolone acetonide and 3 mL of 2% lidocaine under ultrasonographic guidance. The primary outcomes were safety and the Constant score at 1 month. The secondary outcomes were pain, range of motion, muscle strength, functional scores, and overall satisfaction and function. RESULTS: There were no treatment-related adverse events. The Constant score at 1 month did not significantly differ between the PRP and corticosteroid groups. At 6 months, the DASH (Disabilities of the Arm, Shoulder and Hand) score, overall function, and external rotation were significantly better in the PRP group than in the corticosteroid group, and the other clinical outcomes did not show significant differences. All pain measurements, the strength of the supraspinatus and infraspinatus, and 5 functional scores also improved slowly and steadily after injection, becoming significantly better at 6 months compared with those before the injection, whereas those in the corticosteroid group responded promptly but did not further improve. CONCLUSIONS: Allogeneic PRP injections for the treatment of rotator cuff disease are safe but are not definitely superior to corticosteroid injections with respect to pain relief and functional improvement during 6 months. The DASH score, overall function, and external rotation were significantly better in the PRP group than in the steroid group at 6 months. Generally, PRP slowly but steadily reduced pain and improved function of the shoulder until 6 months, whereas corticosteroid did not. LEVEL OF EVIDENCE: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Jo CH, Lee SY, Yoon KS, et al. Allogeneic Platelet-Rich Plasma Versus Corticosteroid Injection for the Treatment of Rotator Cuff Disease: A Randomized Controlled Trial. J Bone Joint Surg Am. 2020. PMID: 33044249. doi:10.2106/JBJS.19.01411

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。